Rehmann Capital Advisory Group’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $947K | Buy |
19,758
+3,570
| +22% | +$153K | 0.04% | 280 |
|
|
2026
Q1 | $595K | Sell |
16,188
-2,364
| -13% | -$112K | 0.03% | 355 |
|
|
2025
Q4 | $944K | Buy |
18,552
+4,664
| +34% | +$239K | 0.05% | 250 |
|
|
2025
Q3 | $771K | Buy |
13,888
+702
| +5% | +$41.1K | 0.04% | 283 |
|
|
2025
Q2 | $910K | Sell |
13,186
-961
| -7% | -$65.4K | 0.06% | 231 |
|
|
2025
Q1 | $982K | Sell |
14,147
-113
| -0.8% | -$9.33K | 0.06% | 223 |
|
|
2024
Q4 | $1.23M | Buy |
14,260
+415
| +3% | +$44.9K | 0.08% | 186 |
|
|
2024
Q3 | $1.65M | Sell |
13,845
-316
| -2% | -$42.1K | 0.11% | 145 |
|
|
2024
Q2 | $2.02M | Sell |
14,161
-437
| -3% | -$57.9K | 0.14% | 121 |
|
|
2024
Q1 | $1.87M | Sell |
14,598
-454
| -3% | -$54K | 0.14% | 121 |
|
|
2023
Q4 | $1.56M | Sell |
15,052
-39
| -0.3% | -$3.86K | 0.13% | 130 |
|
|
2023
Q3 | $1.37M | Sell |
15,091
-1,283
| -8% | -$113K | 0.13% | 126 |
|
|
2023
Q2 | $1.32M | Sell |
16,374
-278
| -2% | -$22.7K | 0.12% | 139 |
|
|
2023
Q1 | $1.33M | Sell |
16,652
-640
| -4% | -$45.4K | 0.12% | 140 |
|
|
2022
Q4 | $1.17M | Sell |
17,292
-1,058
| -6% | -$62K | 0.12% | 151 |
|
|
2022
Q3 | $914K | Sell |
18,350
-342
| -2% | -$18.3K | 0.1% | 174 |
|
|
2022
Q2 | $1.04M | Buy |
18,692
+838
| +5% | +$46.5K | 0.11% | 157 |
|
|
2022
Q1 | $994K | Buy |
17,854
+1,208
| +7% | +$62K | 0.09% | 190 |
|
|
2021
Q4 | $932K | Sell |
16,646
-1,012
| -6% | -$54.8K | 0.09% | 201 |
|
|
2021
Q3 | $848K | Sell |
17,658
-44
| -0.2% | -$2.13K | 0.08% | 214 |
|
|
2021
Q2 | $744K | Buy |
17,702
+112
| +0.6% | +$4.34K | 0.07% | 233 |
|
|
2021
Q1 | $593K | Buy |
17,590
+22
| +0.1% | +$784 | 0.06% | 251 |
|
|
2020
Q4 | $614K | Sell |
17,568
-68
| -0.4% | -$2.35K | 0.07% | 229 |
|
|
2020
Q3 | $612K | Sell |
17,636
-300
| -2% | -$10K | 0.08% | 217 |
|
|
2020
Q2 | $587K | Sell |
17,936
-1,010
| -5% | -$32.2K | 0.08% | 211 |
|
|
2020
Q1 | $570K | Buy |
+18,946
| New | +$564K | 0.09% | 180 |
|
|
2019
Q3 | $61.3K | Sell |
2,372
-8
| -0.3% | -$202 | 0.01% | 569 |
|
|
2019
Q2 | $60.8K | Buy |
2,380
+510
| +27% | +$12.6K | 0.01% | 767 |
|
|
2019
Q1 | $48.9K | Buy |
1,870
+254
| +16% | +$6.24K | 0.01% | 818 |
|
|
2018
Q4 | $37.2K | Buy |
1,616
+36
| +2% | +$800 | 0.01% | 684 |
|
|
2018
Q3 | $37.2K | Sell |
1,580
-2
| -0.1% | -$49 | 0.01% | 913 |
|
|
2018
Q2 | $36.5K | Sell |
1,582
-594
| -27% | -$14.1K | 0.01% | 889 |
|
|
2018
Q1 | $54K | Buy |
+2,176
| New | +$57.1K | 0.01% | 738 |
|
Other funds holding NVO
F
Rehmann Capital Advisory Group's NVO Position: Q2 2026 in Review
Rehmann Capital Advisory Group increased its Novo Nordisk (NVO) stake by 22% in Q2 2026, buying an estimated $153K and bringing the position to 19,758 shares worth $947K. The position accounts for 0.04% of the portfolio, ranked #280.
Rehmann Capital Advisory Group first reported a position in NVO in Q1 2018 and has held it in 33 quarters since. The position peaked at $2.02M in Q2 2024. 1,355 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Rehmann Capital Advisory Group held 19,758 shares of Novo Nordisk worth $947K as of Q2 2026.
- Rehmann Capital Advisory Group bought 3,570 Novo Nordisk shares in Q2 2026, an estimated $153K.
- Novo Nordisk made up 0.04% of Rehmann Capital Advisory Group's portfolio in Q2 2026, its #280 holding.
- Rehmann Capital Advisory Group first reported a position in Novo Nordisk in Q1 2018 and has held it in 33 quarters since.
- Rehmann Capital Advisory Group's Novo Nordisk position peaked at $2.02M in Q2 2024.
- 1,355 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Rehmann Capital Advisory Group's 13F filing for Q2 2026, filed 20 Aug 2026.